Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Tarsus Pharmaceuticals (TARS) Long-Term Debt Issuances (2022 - 2024)

Tarsus Pharmaceuticals (TARS) has 3 years of Long-Term Debt Issuances data on record, last reported at $75.0 million in Q2 2024.

  • For Q2 2024, Long-Term Debt Issuances changed N/A year-over-year to $75.0 million; the TTM value through Sep 2025 reached $75.0 million, changed 0.0%, while the annual FY2024 figure was $75.0 million, 650.0% up from the prior year.
  • Long-Term Debt Issuances reached $75.0 million in Q2 2024 per TARS's latest filing, up from $5.0 million in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $75.0 million in Q2 2024 and bottomed at $5.0 million in Q1 2023.
  • Average Long-Term Debt Issuances over 3 years is $26.2 million, with a median of $12.5 million recorded in 2022.
  • The widest YoY moves for Long-Term Debt Issuances: up 75.0% in 2023, down 75.0% in 2023.
  • A 3-year view of Long-Term Debt Issuances shows it stood at $20.0 million in 2022, then tumbled by 75.0% to $5.0 million in 2023, then soared by 1400.0% to $75.0 million in 2024.
  • Per Business Quant database, its latest 3 readings for Long-Term Debt Issuances were $75.0 million in Q2 2024, $5.0 million in Q3 2023, and $5.0 million in Q1 2023.